Skip to content
    Font Size

    New Treatment for Aggressive Breast Cancer Shows Some Promise

    Early studies found small improvement with combo therapy for HER2-positive disease

    WebMD News from HealthDay

    By Dennis Thompson

    HealthDay Reporter

    WEDNESDAY, Dec. 11, 2013 (HealthDay News) -- Women with aggressive breast cancer who receive combination targeted therapy with chemotherapy prior to surgery have a slightly improved chance of staying cancer-free, researchers say.

    However, the improvement was not statistically significant and the jury is still out on combination treatment, said lead researcher Dr. Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels.

    "I don't think that tomorrow we should switch to a new standard of care," she said.

    Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other research that investigated ways to improve treatment for women with HER2-positive breast cancer. This aggressive form of cancer is linked to a genetic irregularity.

    Other researchers reported the following:

    • The targeted drug trastuzumab (Herceptin) worked better in HER2-positive breast cancer tumors containing high levels of immune cells.
    • A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery treatment option.

    Overall, the studies were good news for women with HER2-positive breast cancer, which used to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted therapy drugs.

    "That tells you these treatments are very, very effective," Piccart-Gebhart said.

    Piccart-Gebhart's combo targeted therapy trial is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) work better when combined on top of standard chemotherapy.

    The trial involved 455 patients with HER2-positive breast cancer with tumors larger than 2 centimeters.

    The women were given chemotherapy prior to surgery along with either Herceptin, Tykerb, or a combination of the two targeted drugs. They also were treated after surgery with whichever targeted therapy they had been receiving.

    Piccart-Gebhart reported that 84 percent of the patients who received the combination targeted therapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin.

    "It's too early today to say this dual treatment saves more lives. We can't say that on the basis of this trial," she noted.

    1 | 2 | 3

    WebMD Video: Now Playing

    Click here to wach video: Dirty Truth About Hand Washing

    Which sex is the worst about washing up? Why is it so important? We’ve got the dirty truth on how and when to wash your hands.

    Click here to watch video: Dirty Truth About Hand Washing